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Previously, compound 19e, a novel heteroaryl-containing benzamide derivative, was
identified as a potent glucokinase activator (GKA) and showed a glucose-lowering effect
in diabetic mice. In this study, the anti-apoptotic actions of 19e were evaluated in INS-1
pancreatic beta-cells co-treated with TNF-α and IL-1β to induce cell death. Compound
19e protected INS-1 cells from cytokine-induced cell death, and the effect was similar to
treatment with another GKA or exendin-4. Compound 19e reduced annexin-V stained
cells and the expression of cleaved caspase-3 and poly (ADP-ribose) polymerase
protein, as well as upregulated the expression of B-cell lymphoma-2 protein. Compound
19e inhibited apoptotic signaling via induction of the ATP content, and the effect was
correlated with the downregulation of nuclear factor-κB p65 and inducible nitric oxide
synthase. Further, 19e increased NAD-dependent protein deacetylase sirtuin-1 (SIRT1)
deacetylase activity, and the anti-apoptotic effect of 19e was attenuated by SIRT1
inhibitor or SIRT1 siRNA treatment. Our results demonstrate that the novel GKA, 19e,
prevents cytokine-induced beta-cell apoptosis via SIRT1 activation and has potential as
a therapeutic drug for the preservation of pancreatic beta-cells.
Keywords: compound 19e, glucokinase activator, beta-cell, apoptosis, cytokine, NAD-dependent protein
deacetylase sirtuin -1
INTRODUCTION
Type 2 diabetes mellitus affected over 300 million people worldwide in 2013, and the prevalence
of diabetes has increased noticeably over the past 50 years with a concomitant increase in the rates
of obesity (Shaw et al., 2010). Diabetes is characterized by hyperglycemia, and insulin released by
pancreatic beta-cells is the key hormone responsible for glucose homeostasis. In type 2 diabetes,
beta-cells are damaged and become dysfunctional because of the persistently high levels of glucose,
lipid, and inflammatory mediators released from the adipose tissues (Kahn et al., 2006). Thus,
maintaining the pancreatic beta-cell mass may be a strategic approach for the prevention and
treatment of diabetes.
Various anti-diabetic drugs targeting pancreatic beta-cells such as sulfonylureas,
thiazolidinediones, incretin mimetics [glucagon-like peptide-1 (GLP-1) analogs] and G-protein
coupled receptor 40 (GPR40) agonists have been developed (Stein et al., 2013). For example,
rosiglitazone, a thiazolidinedione, protects against palmitate-induced cell death in beta-cell lines
(Wu et al., 2013); exenatide, a GLP-1 receptor agonist, increases beta-cell proliferation and
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reduces beta-cell apoptosis in vivo (Vilsboll, 2009); and CNX-
011-67, a GPR40 agonist, increases insulin secretion and reduces
beta-cell apoptosis in the Zucker Diabetic Fatty rat, a diabetic
animal model (Gowda et al., 2013).
Glucokinase, a member of the hexokinase family, is primarily
expressed in hepatocytes, beta-cells, and hypothalamic neurons.
Glucokinase facilitates the phosphorylation of glucose to glucose-
6-phosphate, which is associated with a dual mechanism for
lowering blood glucose concentrations by enhancing glucose
uptake in the liver and increasing insulin secretion from
pancreatic beta-cells (Matschinsky, 2009). Therefore, glucokinase
has been an attractive target for anti-diabetic therapy over
the past two decades. Several glucokinase activator (GKA)
candidates have been shown to reduce blood glucose levels
in diabetic animal models (Eiki et al., 2011; Gill et al.,
2011; Park et al., 2013), including piragliatin, MK-0941,
and AZD1656, which have advanced into clinical trials for
patients with type 2 diabetes (Bonadonna et al., 2010;
Meininger et al., 2011; Kiyosue et al., 2013; Wilding et al.,
2013).
GKA has been shown to exert anti-diabetic effects by
promoting proliferation and preventing apoptosis of beta-cells.
Synthetic GKA compounds promote beta-cell proliferation by
increasing the expression of insulin receptor substrate 2 (IRS-2)
in vivo (Nakamura et al., 2012) and activating the IRS-2-AKT-
Cyclin D2 pathway in INS-1 cells (Oh et al., 2014). Moreover,
GKA shows anti-apoptotic effects against glucotoxicity-,
oxidative stress- and endoplasmic reticulum (ER) stress-
induced beta-cell death. These effects were probably through
an increase in the glucokinase protein levels, phosphorylation
of the apoptotic protein BCL2 associated agonist of cell death
(BAD) and accelerated production of the reduced form of
nicotinamide adenine dinucleotide and reduced form of
nicotinamide adenine dinucleotide phosphate (Wei et al.,
2009; Futamura et al., 2012; Shirakawa et al., 2013). Previously
we reported that the anti-apoptotic effect of YH-GKA was
the result of increase in interaction between glucokinase and
mitochondrial membrane proteins (Oh et al., 2014). The
physiological advantage of GKA-mediated signaling during
glucotoxicity-induced beta-cell apoptosis has been investigated,
but the effect of GKAs on cytokine-induced toxicity in beta-cells
remains unknown.
As cytokines and nutrients trigger beta cell death via
fundamentally different pathways (Cnop et al., 2005), the
protective mechanisms of GKA might also be different depending
on the type of toxic insult. Exposure of beta-cells to interleukin
(IL)-1β combined with tumor necrosis factor (TNF)-α and/or
interferon (IFN)γ causes cell death (Eizirik and Mandrup-
Poulsen, 2001). IL-1β activates mitogen-activated protein kinase
(MAPK) and the nuclear factor-κB (NF-κB) pathways, leading
to the activation of inducible nitric oxide synthase (iNOS) and
increase in nitric oxide (NO), which ultimately induces cell death.
IFNγ induces apoptotic signals through a Janus kinase (JAK)–
signal transducer and activator of transcription (STAT)-mediated
signaling pathway, whereas TNF activates FAS-associated death
domain protein (FADD) and MAPK pathways, which activate a
series of caspase cysteine proteases (Vetere et al., 2014).
Novel synthetic GKAs, compound 19 and compound 19e
(acetyoenyl- or heteroaryl- containing benzamide derivatives),
were previously developed as active GKAs. Both compounds
show glucose-lowering activities in C57BL/6J and db/db mice
with no evidence for hypoglycemia risk (Park et al., 2014, 2015).
The effect of these GKA compounds on beta-cell apoptosis was
evaluated, and as only compound 19e showed anti-apoptotic
effects against cytokine-induced beta-cell death, we investigated
the mechanisms involved. We s found that compound 19e
reduced cytokine-induced apoptotic signaling via inhibition of
cytochrome c release. This was correlated with downregulation
of NF-κB p65 and iNOS and was regulated by increased NAD-




The novel GKAs, compound 19 and 19e, were prepared
by Yuhan Research Institute (Yongin-si, South Korea)
(Park et al., 2014) and were dissolved in dimethylsulfoxide.
(2R)-2-(4-cyclopropanesulphonylphenyl)-N-(5-fluorothiazol-
2-yl)-3-(tetrahydropyran-4-yl) propionamide (PSN-GK1), a
GKA (Fyfe et al., 2007), and exendin-4 (Sigma-Aldrich, St.
Louis, MO, USA), a GLP-1 receptor agonist, were used as
positive controls. The following reagents were purchased from
the indicated suppliers: annexin-V apoptosis detection kit (BD
Transduction Laboratories, Palo Alto, CA, USA); antibodies
against poly (ADP-ribose) polymerase (PARP) and cleaved PARP,
cleaved caspase-3 and procaspase-3 and B-cell lymphoma 2
(Bcl-2) (Cell Signaling Technology, Beverly, MA, USA); and
anti-NF-κB p65, cytochrome c, SIRT1, and secondary
horseradish peroxidase-conjugated anti-mouse and anti-
rabbit antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). All other biochemical reagents were from Invitrogen
(Carlsbad, CA, USA), or Takara (Takara, Shiga, Japan).
Cell Culture
The rat insulinoma cell line, INS-1 (passage 20 ∼ 30), was
grown in Roswell Park Memorial Institute (RPMI)-1640 medium
containing 11 mmol/l glucose. Fetal bovine serum (10%),
100 U/ml penicillin, and 100 µg/ml streptomycin were added
to the culture medium. For experiments involving cytokine
toxicity, INS-1 cells were incubated with 20 ng/ml TNF-α and
20 ng/ml IL-1β for 24 h. 0.025% of DMSO in media was used
as a control. Cell viability was estimated using a cell counting
kit that measures mitochondrial dehydrogenase activity (CCK-8)
(Dojindo Laboratory, Kumamoto, Japan) as described previously
(Oh et al., 2011).
Annexin-V Staining
Early apoptosis was determined using an Annexin-V-phycoery-
thrin apoptosis detection kit, according to the manufacturer’s
instructions. Briefly, the suspended and adherent cells were
pooled, washed twice with ice-cold PBS, and resuspended
in binding buffer. The cell suspension was incubated with
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FIGURE 1 | The proposed molecular mechanisms of the compound 19e-mediated anti-apoptotic effect in INS-1 cells treated with cytokines.
annexin-V-phycoerythrin and 7-amino-actinomycin at room
temperature. After incubation, stained cells were analyzed by flow
cytometry (FACS Calibur, BD Transduction Laboratories) using
CELLQuest software.
Nuclear Protein Extract Preparation
The cells were homogenized in buffer containing 10 mM HEPES-
KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 1 mM dithiothreitol,
0.1% NP40, and protease inhibitors. Nuclei were separated by
centrifugation (7200 × g) for 10 min at 4◦C and resuspended
in nuclei resuspension buffer (10 mM HEPES-KOH, pH 7.9,
400 mM KCl, 0.1 mM EDTA, 25% glycerol, and protease). The
mixture was stirred gently for 10 min at 4◦C and centrifuged
at 1500 × g. The nuclear protein extract was recovered in the
supernatant. Protein concentration was determined by using a
BCA protein assay kit (Pierce, Waltham, MA, USA).
Western Blot Analysis
INS-1 cells were extracted in lysis buffer (50 mM Tris-HCl, pH
7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM NaF,
1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 1 mM
protease inhibitor cocktail). Thereafter, 35 ∼ 40 µg of protein
from the lysates was resolved by 15% SDS-PAGE, transferred
onto nitrocellulose membranes, and blocked with TBS containing
Tween 20 in 3% non-fat dry milk. The membranes were
incubated with specific antibodies and visualized by blotting with
horseradish peroxidase-conjugated secondary antibodies. Signals
were detected using the ECL detection system (Pierce, Rockford,
IL, USA). The intensities of the bands were normalized to the
actin band using Image J software (National Institute of Health,
Bethesda, MD, USA).
Quantitative Real-Time PCR
Isolation of total RNA was performed according to the
manufacturer’s recommended protocol for Trizol. Extracted RNA
was treated with DNase I and reverse transcribed to single-
strand cDNA using oligo(dT) primer with PrimeScriptTM RTase
(Takara). Quantitative real-time PCR (qRT-PCR) analysis was
performed using SYBR mater mix (Applied Biosystems) using
the ABI 7900 Real-time PCR system according to the protocols
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FIGURE 2 | Effect of GKA compounds on cell viability. (A) Structure of compound 19 (C19) and compound 19e (C19E) (B) INS-1 cells were treated with various
concentrations of C19 or C19E for 24 h, and viability was determined using a cell counting kit. (C) INS-1 cells were treated with 20 ng/ml of IL-1β and 20 ng/ml
TNF-α (CM) in the absence or presence of various concentrations of C19 or C19E. After 24 h, cell viability was determined by using a cell counting kit. Results
represent the mean ± SEM from triplicate experiments. ∗P < 0.05 vs. 0, ∗∗P < 0.05 vs. CON, †P < 0.05 vs. CM alone.
provided by the manufacturer (Applied Biosystems). The
sequences of the primer pairs are as follows: iNOS (forward) 5′-C
TCACTGTGGCTGTGGTCACCTA-3′ and (reverse) 5′-GGGT
CTTCG GGCTTCAGGTTA-3′, SIRT1 (forward) 5′-GAGCA
GGTTGCAGGAATCCA-3′ and (reverse) 5′-GCAAGATGCT
GTTGCAAAGG-3′ and cyclophilin (forward) 5′-GGTCTTTG
GGAAGGTGAAAGAA-3′ and (reverse) 5′-GGTCTTTGGGA
AGGTGAA AGAA-3′. The relative mRNA transcript levels were
calculated according to the 2−1CT method, in which 1CT
represents the difference in threshold cycle values between the
target mRNA and the cyclophilin internal control.
Measurement of Cellular Adenosine
Triphosphate
Intracellular adenosine triphosphate (ATP) content was
measured using a CellTiter-Glo luminescence kit (Promega
Life Science, Madison, WI, USA). The test was performed
according to the manufacturer’s recommendations. Cells were
mixed with the CellTiter-Glo reagent and lysed by vortexing.
After incubating at room temperature for 10 min, luminescence
was recorded by a microplate reader. The quantity of ATP was
calculated using an ATP standard curve and the ATP content
was normalized by the protein amount.
Measurement of SIRT1 Deacetylase
Activity
Nuclear protein was extracted and SIRT1 deacetylase activity
was measured using a SIRT1 activity assay kit according to
the manufacturer’s protocol (Abcam, Cambridge, MA, USA).
Fluorescence intensity was measured for 30 min at 2 min
intervals using a microtiter plate fluorometer with excitation at
340 nm and emission at 460 nm. SIRT1 deacetylase activity was
normalized by the protein content.
siRNA Transfection
The cells were transiently transfected with 100 nM of SIRT1
siRNA or scrambled siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) using Lipofectamine RNAi MAX (Invitrogen,
Carlsbad, CA, USA) reagent in accordance with manufacturer’s
protocol. After 24 h, the medium was replaced with cytokine
mixtures with or without GKAs.
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FIGURE 3 | Anti-apoptotic effect of compound 19e on cytokine-induced toxicity. INS-1 cells were treated with 20 ng/ml of IL-1β and 20 ng/ml TNF-α (CM)
with or without (-) 10 µM of PSN-GK-1 (GK-1), 5 nM of exendin-4 (EX-4) or 5 µM of compound 19e (C19E) for 24 h. (A) Cell viability was determined by using a cell
counting kit. (B) Cells were harvested and stained with annexin-V-phycoerthyrin. Apoptotic cells were counted by flow cytometry. (C) Cell lysates were subjected to
western blot analysis using specific antibodies. (D) Densities of western blot signals were measured using Image J software and relative expression was normalized
to actin. The results represent the mean ± SEM from triplicate experiments. ∗P < 0.05 vs. CON, †P < 0.05 vs. CM alone.
Statistical Analysis
Data were expressed as the mean ± SEM and were analyzed
using one-way, two-way, or repeated measurements analysis of
variance (ANOVA). Differences between the treatment groups
were analyzed by the Duncan’s multiple range test.
RESULTS
Compound 19e Treatment Protects INS-1
Cells from Cytokine Mixture-Induced Cell
Death
Figure 1 shows the proposed pathway for the action of compound
19e. To elucidate this pathway, we first examined whether
synthesized GKA compounds (compound 19 and compound
19e) (Figure 2A), previously identified as potent GKAs (Park
et al., 2014, 2015), exert toxicity on INS-1 cells. After 24 h of
treatment, cytotoxicity was not observed at any concentration
(2.5 ∼ 40 µM), and an increased cell viability was demonstrated
with concentrations of 5, 10, and 20 µM of the compounds
(Figure 2B). To investigate whether the compounds exert anti-
apoptotic effects, INS-1 cells were incubated with a cytokine
mixture, which is known to induce beta-cell death, in the absence
or presence of compound 19 or 19e (2.5 ∼ 40 µM), and the cell
viability was determined. After 24 h of treatment, the mixture of
interleukin (IL)-1β and TNF-α (20 ng/ml of IL-1β and 20 ng/ml
of TNF-α) caused a marked reduction of viable cells compared
with the control cells, and compound 19e significantly reduced
the toxic effect (Figure 2C). Compound 19 did not exert a
protective effect at either low or high concentrations.
Compound 19e Treatment Reduced
Cytokine Mixture-Induced Beta-Cell
Apoptosis
As compound 19e treatment reduced cytokine-induced beta-
cell death, we investigated whether compound 19e could protect
beta-cells against apoptosis induced by the cytokine mixture
and the effect was compared to treatment with PSN-GK1
or exendin-4 (Ferdaoussi et al., 2008; Oh et al., 2014). In a
preliminary study, we found that 10 µM of PSN-GK1 or 5 nM
of exendin-4 effectively suppressed cytokine-induced beta cell
apoptosis (Oh et al., 2013). We confirmed that compound 19e
(5 µM) decreased cytokine-induced beta-cell death and this effect
was similar to that with PSN-GK1 or exendin-4 (Figure 3A).
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FIGURE 4 | The protective effect of compound 19e against cytokine-induced mitochondrial dysfunction by suppression of NF-κB signaling. INS-1 cells
were treated as described in Figure 2. (A) Cell lysates were fractionated and the nuclear fraction was subjected to western blot analysis using specific antibodies.
(B) Densities of western blot signals were measured using Image J software and relative expression was normalized to lamin B. (C) iNOS mRNA levels were
analyzed by qRT-PCR and cyclophilin was used as a loading control. N.D, non-detected. (D) Cell lysates were subjected to western blot analysis using specific
antibodies. Actin was used as a loading control. (E) Intracellular concentrations of ATP were determined using an ATP-dependent luminescent cell viability assay.
Mean ± SEM from triplicate experiments. ∗P < 0.05 vs. CON, †P < 0.05 vs. CM alone.
The occurrence of apoptosis and the protein levels of apoptosis-
related proteins were evaluated in cytokine mixture-treated cells
in the absence or presence of compound 19e. The number of
annexin V stained cells was significantly increased by cytokine
toxicity, but a reduction was observed after treatment with 5 µM
of compound 19e (Figure 3B). Moreover, the protein levels of
cleaved caspase-3 and cleaved PARP induced by the cytokine
mixture was significantly reduced by compound 19e treatment
(Figures 3C,D). The anti-apoptotic protein, Bcl-2, was increased
in cytokine-treated cells subjected to compound 19e treatment.
Similar results on apoptosis and expression of proteins were seen
with PSN-GK1 and exendin-4 (Figures 3B–D).
Compound 19e Prevented
Cytokine-Induced Apoptosis by
Recovery of Mitochondrial Dysfunction
It has been reported that cytokines stimulate NF-κB-mediated
NO production (Eizirik et al., 1996; Darville and Eizirik, 2001),
and the upregulation of NO causes mitochondrial dysfunction
in beta-cells (Cetkovic-Cvrlje and Eizirik, 1994). Therefore, the
effect of compound 19e on cytokine-stimulated NF-κB activation
was evaluated. Cells treated with cytokines alone showed
increased transcriptional activity of NF-κB p65, as demonstrated
by western blot after nuclear fractionation. However, cytokine-
treated cells also treated with compound 19e, PSN-GK1, or
exendin-4 showed a significant decrease in NF-κB p65 protein
levels (Figures 4A,B). Similar to the results obtained with
NF-κB activity, cytokines alone upregulated iNOS mRNA
levels, and compound 19e treatment downregulated this effect
(Figure 4C). Finally, to determine whether mitochondrial
function was correlated with the anti-apoptotic effect of
compound 19e, cytochrome c release was measured, which is a
primary indicator of mitochondrial function in beta-cells (Ma
et al., 2012). As shown in Figure 4D, treatment of cells with
cytokines alone for 24 h increased the release of cytochrome c
into the cytosol, and this release was decreased by co-treatment
with compound 19e. Total cellular ATP content was significantly
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FIGURE 5 | Effect of compound 19e on SIRT1 deacetylase activity. INS-1 cells were treated as described in Figure 2. (A) Cell lysates were subjected to
western blot using specific antibodies. (B) Densities of western blot signals were measured using Image J software and relative expression was normalized to actin.
(C) Nuclear protein was extracted and SIRT1 deacetylase activity was measured using fluorogenic substrate. The results represent the mean ± SEM from triplicate
experiments. ∗P < 0.05 vs. CON, †P < 0.05 vs. CM alone.
decreased by cytokine toxicity, but was attenuated in cells treated
with 5 µM of compound 19e (Figure 4E). Exendin-4-treated
cells also demonstrated recovery from mitochondrial dysfunction
induced by cytokine treatment (Figure 4E).
Compound 19e Reduces
Cytokine-Induced Apoptosis via
Modulation of SIRT1 Activity
Since SIRT1 has been reported to interfere with NF-κB signaling
and exhibit anti-inflammatory actions (Yang et al., 2007), we
investigated whether SIRT1 is involved in the anti-apoptotic
effect of compound 19e. Western blot analysis was performed,
and the enzyme activity of cytokine-treated cells co-treated
with GKAs or exendin-4 was examined. SIRT1 expression
did not differ between the control and cytokine-treated cells
(Figures 5A,B). However, deacetylase activity was significantly
reduced in cells treated with cytokines alone, and compound 19e
attenuated the reduction of SIRT1 activity (Figure 5C).
To confirm that SIRT1 activation is involved in the anti-
apoptotic effect of compound 19e, cells were treated with a
SIRT1 deacetylase inhibitor or SIRT1 siRNA, and cell viability
was determined. As shown in Figure 6A, treatment with the
SIRT1 deacetylase inhibitor, nicotinamide (2.5 mM), inhibited
the protective effect of compound 19e on cytokine-induced cell
death (Figure 6A). Similarly, both PSN-GK1 and exendin-4
also significantly activated SIRT1 deacetylase activity, and
nicotinamide treatment abolished the protective effect of these
compounds (Figure 6A). SIRT1 expression was dramatically
reduced after 24 h of SIRT1 siRNA transfection (Figure 6B),
and the protective effect of compound 19e treatment on
cytokine-induced cell death was inhibited in SIRT1 siRNA-
treated cells compared with scrambled siRNA-treated cells
(Figure 6C).
DISCUSSION
Glucokinase is an attractive target for the treatment of
type 2 diabetes owing to its anti-apoptotic and proliferative
effects on pancreatic beta-cells. A number of allosteric small-
molecule GKAs have been developed, and their efficacy
has been investigated on beta-cells and in diabetic mice.
Previously, compound 19e was discovered as a novel glucokinase,
demonstrating hypoglycemic effects in diabetic db/db mice
(Park et al., 2014). In this study, the anti-apoptotic effects and
mechanisms of compound 19e were investigated in INS-1 beta-
cells treated with cytokines to induce cell death.
It has been reported that GKAs prevent beta-cell death
induced by oxidative stress, glucotoxicity, and ER stress.
Futamura et al. (2012) demonstrated that Cpd-C (a synthetic
GKA compound) increases NADH production and results in
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FIGURE 6 | Amelioration of cytokine-induced cell death by SIRT1 activity inhibitor or SIRT1 siRNA treatment. (A) INS-1 cells were pre-treated with
2.5 mM nicotinamide (NAM) for 12 h and incubated with GK-1, EX-4, or C19E in the presence of CM for 24 h. Cell viability was determined by using a cell counting
kit. (B) SIRT1 siRNA (siSIRT1) or scrambled siRNA (siCON) was transfected into INS-1 cells and SIRT1 mRNA levels were analyzed by qRT-PCR. Cyclophilin was
used as a loading control. (C) Cells were transfected with SIRT1 siRNA (siSIRT1) or scrambled siRNA (siCON) for 24 h and then incubated with GK-1, EX-4, or C19E
in the presence of CM for 24 h. Cell viability was determined by using a cell counting kit. Results represent the mean ± SEM from triplicate experiments. ∗P < 0.05
vs. CON, †P < 0.05 vs. CM alone.
prevention of hydrogen peroxide-induced beta-cell apoptosis.
GKA 50 and YH-GKA prevent INS-1 cell loss induced by chronic
high glucose, and the effects were probably as a result of increase
of BAD protein and interaction with glucokinase and voltage-
dependent anion channel proteins within the mitochondrial
membrane (Wei et al., 2009; Oh et al., 2014). Also, GKA
ameliorates ER stress-induced apoptosis by upregulation of
IRS-2 expression (Shirakawa et al., 2013). In this study, we
demonstrated a previously unidentified function of GKAs – the
ability to protect against cytokine-induced beta-cell apoptosis.
One of the important pathogenetic mechanisms of beta-
cell damage during diabetes is the increased expression of
proinflammatory cytokines such as IL-1β, interferon (IFN)-γ,
and TNF-α (Cnop et al., 2005). During the development of
type 2 diabetes, there is an increased secretion of TNF-α from
infiltrated macrophages in the adipose tissues, which induces the
production of several inflammatory cytokines, including IL-1β
(Hanafusa and Imagawa, 2008). It has been demonstrated by
previous studies and our group that treatment of insulinoma cells
or isolated islets with cytokine mixtures reduces cell viability and
insulin secretion in response to glucose (Kim et al., 2007; Oh et al.,
2011). Therefore, the preventive effect of compound 19e against
the deleterious effects of proinflammatory cytokines would
be beneficial to preserve functional beta-cell mass. Moreover,
compound 19e treatment increased the number of beta-cells via
upregulation of IRS-2 expression (data not shown), suggesting
that a proliferative effect as well as an anti-apoptotic effect might
be mechanisms by which compound 19e induced significant
reduction in blood glucose levels in db/db mice (Park et al.,
2014).
Under diabetic conditions, IL-1β activates NF-κB and
consequently regulates the expression of proinflammatory genes,
such as Fas, and iNOS (Eizirik et al., 1996; Darville and
Eizirik, 2001). Moreover, cytokine-induced NF-κB activation
disrupts the mitochondrial membrane potential, which is
prevented by overexpression of the anti-apoptotic protein Bcl-2
(Barbu et al., 2002). Therefore, inhibition of NF-κB activation
protects pancreatic beta-cells against cytokine-induced apoptosis
(Eizirik and Mandrup-Poulsen, 2001; Heimberg et al., 2001).
Compound 19e protected INS-1 cells from cytokine toxicity
via the suppression of NF-κB-dependent iNOS expression and
cytochrome c release, thereby enhancing ATP content.
SIRT1, a class III histone/protein deacetylase, interferes
with the NF-κB signaling pathway and thereby exhibits
anti-inflammatory and anti-apoptotic properties (Yang et al.,
2007). Lee et al. (2009) reported that SIRT1 protein levels were
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downregulated in RIN (rat insulinoma) cells treated with
a cytokine mixture (combination of TNF-α and IFN-γ),
and the overexpression of SIRT1 protected against cytokine
toxicity by suppressing NF-κB. However, it was reported
that SIRT1 deacetylase activity, rather than SIRT1 protein
levels, is more relevant in the progression of diabetes and
its complications (Nascimento et al., 2013). We observed that
SIRT1 activity, but not protein levels, decreased in cytokine-
treated cells and compound 19e recovered SIRT1 activity.
Moreover, inhibition of SIRT1 activity by nicotinamide or
SIRT1 siRNA treatment did not enhance the viability in cells
treated with compound 19e. Resveratrol, a SIRT1 activator,
exhibits protective actions against cytokine-induced beta-
cell dysfunction by activating nicotinamide-dependent protein
deacetylase SIRT1 (Lee et al., 2009). These results suggest
that compound 19e enhanced SIRT1 activity and consequently
inhibited cytokine-induced NF-κB signaling pathways in INS-1
cells.
The mechanism by which compound 19e increases SIRT1
deacetylase activity is unclear, however, a study showing that
SIRT1 activation upregulates glucokinase in beta-cells (Vetterli
and Maechler, 2011) suggests that GKA is associated with SIRT1
activity. SIRT1 is not only regulated by the NAD+/NADH
ratio, but also by endogenous proteins involved in signal
transduction (Nogueiras et al., 2012). It will be investigated
whether compound 19e directly or indirectly regulates SIRT1
activity.
A previous study has shown that exendin-4 attenuates beta-
cell apoptosis via the phosphoinositide 3-kinase/protein kinase B
(PI3K/PKB), cyclic adenosine monophosphate – protein kinase
A (cAMP-PKA), c-jun-N-terminal kinase (JNK), and p38-MAPK
pathways (Lee and Jun, 2014). Especially, under conditions of
cytokine-induced (IL-1β and/or TNF-α) apoptotic cell death,
NF-κB and PKA-dependent JNK phosphorylation are involved
in the protective activity of exendin-4 in a mouse beta-cell line,
MIN-6 cells (Natalicchio et al., 2010; Liu et al., 2013). The
anti-apoptotic effect of PSN-GK1 is not well-known; however,
GKAs possibly prevent beta-cell death via regulation of IRS-2
(Shirakawa et al., 2013). In this study, we found that SIRT1-
mediated inhibition of NF-κB was involved in the protective
effect of exendin-4 and PSN-GK1 against cytokine toxicity.
Therefore, it would be interesting to investigate whether a
combined treatment of exendin-4 and GKAs exerts additive
effects to reduce glucose levels and beta-cell apoptosis in diabetic
mice.
CONCLUSION
Compound 19e inhibited apoptosis induced by a cytokine
mixture in INS-1 cells, and SIRT-1 mediated downregulation
of NF-κB and iNOS was involved in this effect. These results
suggest that compound 19e may be a potential therapeutic drug
to preserve beta-cell mass, at least in part, for the treatment of
type 2 diabetes.
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